The American Society of Clinical Oncology (ASCO) is gearing up for its annual meeting. At this meeting, cancer drug developers will share the results from their most recent drug trials.
Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue to stay around.
The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
However, one medical supply company stood out, as short sellers piled on Baxter International in the first two weeks of the month.
ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or losers from the meeting can be divined ahead of time by these…
Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more than $5 billion.
The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from June 3 to…
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical stocks short interest decreased.
As the markets reached all-time highs last month, the short sellers were in retreat, judging by the moves in the most heavily shorted stocks traded on the New York Stock Exchange.
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Bats Global Markets, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer and SolarCity.
These stocks should do well for years regardless of who the next president is. They all have incredible franchises, long and mature product silos and, importantly, very strong consumer brand awareness.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the position that Medivation found itself in.
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates…
May 3, 2016: Markets opened lower Tuesday following some overnight weakness in overseas markets resulting from weak data on trade from both China and Europe and a strengthening dollar. Energy prices were…
Pfizer reported better-than-expected first-quarter 2016 results before markets opened Tuesday morning.
Paul Ausick 
